Inventor

Karl Y. Hostetler

Inventor

Del Mar, CA, US

Overview

1987–2021

Patent span

Human necessities

Primary field (CPC A)

Patents· 67 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary

A61KPreparations for medical, dental or toiletry purposes25%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations22%

C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium21%

C07HSugars14%

Y02ATechnologies for adaptation to climate change7%

B82YSpecific uses or applications of nanostructures4%

C07KPeptides2%

C07CAcyclic or carbocyclic compounds1%

C07DHeterocyclic compounds1%

C12NMicroorganisms or enzymes1%

PatentTitleYear

11,014,950Nucleotide analogs2021 10,702,532Nucleotide analogs2020 10,449,207Acyclic nucleoside phosphonate diesters2019 10,377,782Nucleotide analogs2019 10,213,430Nucleotide analogs2019 10,195,222Acyclic nucleoside phosphonate diesters2019 10,076,533Acyclic nucleoside phosphonate diesters2018 10,076,532Acyclic nucleoside phosphonate diesters2018 10,071,110Phosphonate compounds2018 9,801,884'Nucleotide analogs'2017 9,775,852'Acyclic nucleoside phosphonate diesters'2017 9,649,321'Phosphonate compounds'2017 9,629,860'Acyclic nucleoside phosphonate diesters'2017 9,493,493'Nucleotide analogs'2016 9,475,832'Phosphonates with reduced toxicity for treatment of viral infections'2016 9,387,217'Acyclic nucleoside phosphonate diesters'2016 9,206,208'Phosphonate compounds'2015 9,156,867'Acyclic nucleoside phosphonate diesters'2015 8,889,658'Phosphonate compounds'2014 8,846,643'Phosphonates with reduced toxicity for treatment of viral infections'2014 8,835,630'Acyclic nucleoside phosphonate diesters'2014 8,710,030'Phosphonate compounds'2014 8,318,700'Lung-targeted drugs'2012 8,309,565'Phosphonate compounds'2012 8,222,257'Phosphono-pent-2-en-1-yl nucleosides and analogs'2012 8,193,167'Pharmacologically active agents containing esterified phosphonates and methods for use thereof'2012 8,101,745'Lung-targeted drugs'2012 8,017,135'Lipid-drug conjugates for local therapy of eye diseases'2011 8,008,308'Phosphonate compounds'2011 7,994,143'Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates'2011 7,790,703'Phosphonate compounds'2010 7,749,983'Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates'2010 7,687,480'Phosphonate compounds'2010 7,652,001'Pharmacologically active agents containing esterified phosphonates and methods for use thereof'2010 7,517,858'Prodrugs of pharmaceuticals with improved bioavailability'2009 7,452,898'Phosphonate compounds'2008 7,098,197'Phosphonate compounds'2006 7,094,772'Phosphonate compounds'2006 7,034,014'Phosphonate compounds'2006 6,716,825'Phosphonate compounds'2004 6,686,462'Antiviral compounds and methods of administration'2004 6,599,887'Methods of treating viral infections using antiviral liponucleotides'2003 6,448,392'Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use'2002 6,252,060'Antiviral liponucleosides: treatment of hepatitis B'2001 6,015,573'Nucleoside phosphate therapy for viral infection'2000 6,002,029'Antiviral prodrugs'1999 5,879,700'Nucleoside analogue phosphates for topical use'1999 5,827,831'Lipid nucleotide analog prodrugs for oral administration'1998 5,817,638'Antiviral liponucleosides: treatment of hepatitis B'1998 5,804,552'Lipid conjugates of therapeutic peptides and protease inhibitors'1998 5,780,617'Synthesis of liponucleotides'1998 5,756,116'Nucleoside phosphate therapy for viral infection'1998 5,744,461'Lipid derivatives of phosphonoacids for liposomal incorporation and method of use'1998 5,744,592'Lipid prodrugs for oral administration'1998 5,696,277'Antiviral prodrugs'1997 5,654,286'Nucleotides for topical treatment of psoriasis, and methods for using same'1997 5,580,571'Nucleoside analogues'1996 5,554,728'Lipid conjugates of therapeutic peptides and protease inhibitors'1996 5,484,809'Prodrugs for oral administration containing taxol or substituted taxol covalently bound to a phospholipid'1996 5,463,092'Lipid derivatives of phosphonacids for liposomal incorporation and method of use'1995 5,411,947'Method of converting a drug to an orally available form by covalently bonding a lipid to the drug'1995 5,364,840'Synthetic calcitonin peptides'1994 5,223,263'Liponucleotide-containing liposomes'1993 5,194,654'Lipid derivatives of phosphonoacids for liposomal incorporation and method of use'1993 5,175,146'Synthetic calcitonin peptides'1992 4,837,380'Liposome-calcitonin preparation'1989 4,692,433'Method and composition for regulating serum calcium levels of mammals'1987

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1987–2021Patents assigned to UNIV CALIFORNIA (42)· patent assignee history

1987–2021Based in Del Mar, CA, US· patent location history

1996–2001Patents assigned to NEXSTAR PHARMACEUTICALS INC (8)· patent assignee history

1997–2012Patents assigned to HOSTETLER KARL Y (6)· patent assignee history

2002–2011Patents assigned to CHIMERIX INC (4)· patent assignee history

2012Patents assigned to BEADLE JAMES R (4)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
UNIV CALIFORNIA	42	1987–2021
NEXSTAR PHARMACEUTICALS INC	8	1996–2001
HOSTETLER KARL Yself	6	1997–2012
BEADLE JAMES R	4	2012
CHIMERIX INC	4	2002–2011

Locations

Location	Patents	Span
Del Mar, California, US	67	1987–2021